

# Atrial Fibrillation in Primary Aldosteronism

## Authors

Chien-Ting Pan<sup>1, 2</sup>, Cheng-Hsuan Tsai<sup>2, 3</sup>, Zheng-Wei Chen<sup>1, 2</sup>, Yi-Yao Chang<sup>4</sup>, Vin-Cent Wu<sup>5</sup>, Chi-Sheng Hung<sup>2, 6</sup>, Yen-Hung Lin<sup>2, 6</sup>, the TAIPEI Study Group

## Affiliations

- 1 Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan
- 2 Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- 3 Department of Internal Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan
- 4 Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan
- 5 Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- 6 Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan

## Key words

atrial fibrillation, primary aldosteronism, aldosterone, atrial remodeling

received 16.12.2019

accepted 09.03.2020

## Bibliography

DOI <https://doi.org/10.1055/a-1141-5989>

Published online: 14.4.2020

Horm Metab Res 2020; 52: 357–365

© Georg Thieme Verlag KG Stuttgart · New York

ISSN 0018-5043

## Correspondence

Yen-Hung Lin MD, PhD

Department of Internal Medicine, National Taiwan University Hospital

No. 7, Chung-Shan South Road

100 Taipei

Taiwan

Tel.: +886 2 23123456, ext.62152, Fax: +886 2 23515811

[austinr34@gmail.com](mailto:austinr34@gmail.com)

## ABSTRACT

Primary aldosteronism (PA) is the most common cause of secondary hypertension. Increasing evidence has demonstrated an increased cardiovascular risk in patients with PA compared to those with essential hypertension (EH), including atrial fibrillation (AF), the most prevalent arrhythmia among adults that is associated with an elevated risk of subsequent cerebro-cardiovascular adverse events. The mechanisms of increased prevalence of AF in PA patients are complex. Excessive aldosterone production is regarded to be a key component in the pathogenesis of AF, in addition to arterial hypertension and electrolyte imbalance. In addition, several translational and clinical studies have reported that structural remodeling with atrial fibrosis and electrical remodeling with arrhythmogenicity induced by an excess of aldosterone also play major roles in AF genesis. Clinical studies from several registries and meta-analysis have reported an increased prevalence and risk of AF in PA patients compared to EH patients. Recent trials have further demonstrated a reduction in the risk of new-onset atrial fibrillation (NOAF) after adrenalectomy, while the results of medical treatment with mineralocorticoid receptor antagonists (MRAs) have been inconsistent. This review outlines the current evidence of the relationship between PA and AF, and highlights recent progress in the management of PA with regards to the development of AF.

## Introduction

Primary aldosteronism (PA) manifests as secondary hypertension and is defined as excessive autonomous endogenous aldosterone

production unresponsive to renin regulation, further leading to elevated blood pressure and electrolyte imbalance. PA has a prevalence of 4.3–9.5% in all patients with hypertension, 13% of those with stage 3 hypertension, and 17–23% of those with resistant hy-

pertension [1]. Higher rates of long-term mortality and co-morbidities have been reported in PA patients compared to patients with essential hypertension (EH) [1–3]. Atrial fibrillation (AF) is the most common arrhythmia in adults, and has a prevalence of 3% in adults aged over 20 years, and more in the elderly and patients with chronic illnesses, and it has been shown to increase the risk of all-cause mortality and major cardiac and cerebrovascular complications [4]. In patient with PA, AF is the most common seen arrhythmia with a prevalence of 7.1–7.3% [2, 5]. In German Conn's study, AF occurred in 7.1%; other atrial or ventricular arrhythmia occurred in 5.2% of the patients [5].

The pathogenesis of AF is complex, and involves abnormal cardiac electrical activity from the atrium and adjacent structures with subsequent cardiac electrical, structural, neural and autonomic remodeling [6]. The progressive remodeling and degradation with fibrosis of the atrium and other cardiac structure combined with AF has been shown to increase the risk of thromboembolism [7].

Previous studies on the association between aldosterone and AF have mostly been conducted on clinical patients with heart failure and related mineralocorticoid receptor antagonists (MRAs) treatment as upstream or conjunctive therapy. In addition, several animal and cell experiments have reported aldosterone-induced cardiac structural changes or electrophysiological alterations at the pathological or molecular level [8]. The pro-fibrotic and pro-arrhythmogenic effects of aldosterone and mineralocorticoid receptor (MR) activation have been proposed in these studies. This implies that excessive aldosterone in PA patients may be associated with the development of AF, and that effective treatment of PA may decrease the risk of further occurrences of AF.

This review evaluates the current evidence of the relationship between PA and AF, from the pathogenesis of AF with a clinical or basic approach to concurrent clinical trials about PA treatment.

## Pathophysiology of the occurrence of AF in PA patients


### AF genesis

The leading hypothesis for the genesis of AF is initiation by ectopic firing and perpetuation by reentry [6]. The molecular basis for focal ectopic firing from myocyte sleeves within the pulmonary veins [9] and atrial tissue as the disease progresses [6] is attributed to a diastolic leak of  $\text{Ca}^{2+}$  from the sarcoplasmic reticulum, resulting in  $\text{Na}^+$  inward current via  $\text{Na}^+-\text{Ca}^{2+}$  exchange, and subsequently spontaneous myocyte depolarization [10]. There are two main possible mechanisms of AF reentry, including reentrant rotors or multiple independent wavelets [6]. Slow conduction wavefront velocity, indicating structural remodeling, and short effective refractory periods (ERPs) of the atrium, indicating electrical remodeling, promote and perpetuate the reentry [6]. In addition, fibrotic changes, abnormalities of atrial cardiomyocytes or interstitial matrix of the atrium all also contribute to reentry [6].

For patients with PA, there are several possible mechanisms for the development of AF, including arterial hypertension and ventricular remodeling, hypokalemia, atrial structural and electrical remodeling caused by excess aldosterone (► Fig. 1).

### Atrial structural remodeling

Cardiac fibrosis results from excessive activation of cardiac fibroblasts and myofibroblasts [11], and atrium-specific fibrosis presents with fibrotic atrial cardiomyopathy and promotes AF with an elevated risk of thromboembolism [7]. Excess aldosterone has been shown to cause cardiac fibrosis in many previous studies [12, 13]. Prior to the development of fibrosis, aldosterone and MR activation facilitate inflammation by inducing the production of reactive oxygen species (ROS), which activate proinflammatory transcription factors [14] in macrophages [15] and the heart [16]. Furthermore, aldosterone



► **Fig. 1** Pathogenesis of atrial fibrillation in primary aldosteronism. Primary aldosteronism (PA) is characteristic of aldosterone excess, which causes atrial fibrillation (AF) by the following mechanisms. Aldosterone excess causes arterial hypertension and hypokalemia, both related to increased risk of AF. Direct effect of excessive aldosterone working on cardiac structure favoring could be summarized into two: atrial structural remodeling and atrial electrical remodeling. Atrial structural remodeling is caused by increased left ventricle and atrium fibrosis with systemic inflammation involved, through the emergence of diastolic and systolic dysfunction; atrial electrical remodeling is caused by aldosterone-induced atrial fibrosis, altered calcium and potassium channel function, intra-cellular sodium-calcium dysregulation, further promotion of reentry and shortening of action potential to cause AF.

causes cardiac interstitial macrophage infiltration [17], and activates the MRs on macrophages to promote the expressions of profibrotic genes, including transforming growth factor  $\beta$ 1 (TGF- $\beta$ 1) [18] and plasminogen activator inhibitor-1 (PAI-1) [19]. PAI-1 inhibits plasmin-dependent matrix metalloproteinase (MMP) activation to limit collagen degradation and thus increase fibrosis [20]. TGF- $\beta$  can enhance the formation of myofibroblasts, which express alpha-smooth muscle actin ( $\alpha$ -SMA), to drive collagen formation [21]. Myofibroblasts, which are derived from fibroblasts, play a particularly crucial role in cardiac fibrosis due to a nearly two-fold higher capacity of collagen synthesis and higher capacity of synthesizing many cytokines and chemokines [22]. Aldosterone has been shown to induce the transdifferentiation of neonatal rat cardiac fibroblasts to myofibroblasts via Keap1/Nrf2 signaling pathways [23].

Atrial structural remodeling is a major promoting factor of reentry [6]. An excess of aldosterone can cause increased atrial fibrosis [24] and further conduction interference. Reil et al. found that aldosterone-infused rats had increased atrial size, fibroblasts and interstitial collagen, but reduced active MMP-13, a collagen degrading enzyme in both atriums [25]. They also found that P-wave duration, total right atrium activation time, and anisotropy of local conduction time, as an index of atrial structure remodeling, were all prolonged in aldosterone-infused rats compared with controls [25]. Heterogeneous pathways of slow conduction and atrial dilatation both provide larger pathways that are more ready for sustained reentrant circuits [26]. The effects of structural atrial remodeling on the development of AF were most clearly demonstrated in a cardiac myocyte-specific transgenic mouse model overexpressing TGF- $\beta$ 1. This model resulted in atrial fibrosis, and the increase in atrial fibrosis significantly increased susceptibility to AF [21].

### Atrial electrical remodeling

Aldosterone-induced atrial fibrosis-related re-entry circuits are another possible mechanism of AF in PA patient. Fibrotic tissue decreases gap junction coupling and causes muscle bundle discontinuities which reduce and promote re-entry circuits [27]. Electrophysiological changes have also been documented with aldosterone-treated cells and animal models. In an aldosterone infusion rat model, Lamers et al. reported prolonged duration of AF after transesophageal atrial burst stimulation [28]. Interestingly, aldosterone infusion did not affect ventricular function or atrial pressure in their study, but lengthened P-wave duration. P-wave duration is a marker of atrial conduction time and is associated with a higher risk of AF [29, 30]. Furthermore, aldosterone infusion has been associated with a significant shortening of action potential and increased protein expressions of Kir2.1 and Kv1.5 [28]. Inwardly-rectifying potassium channels (Kir) are characterized by the property of inward-rectification, which is defined as the ability to allow large inward currents and smaller outward currents. The activation of Kir would therefore promote the formation of AF. This implies that electrical condition abnormalities and hypokalemia may cause AF in patient with PA.

Ouvrard-Pascaud et al. reported that aldosterone increased L-type  $\text{Ca}^{2+}$  channels in neonatal rat atrial mouse cells, and decreased the activity of the rapidly activating delayed rectifier potassium current  $\text{IKr}$  and transient outward  $\text{K}^{+}$  current  $\text{Ito1}$  [31]. Aldosterone has also been shown to promote the prolonged release of  $\text{Ca}^{2+}$  from the sarcoplasmic reticulum due to opening of ryanodine

receptors, finally leading to  $\text{Ca}^{2+}$  overload and thereby promoting AF [32]. Aldosterone has also been shown to increase  $\text{I}_{\text{CaT}}$  and induce calcium overload [33]. This aldosterone-induced calcium overload will produce a positive feedback vicious cycle of atrial electrical remodeling and leading to AF.

In a special group of PA patients (familial hyperaldosteronism type III) who were characterized by having germline mutation of *KCNJ5* (potassium inwardly-rectifying channel, subfamily J, member 5) [34], *KCNJ5* mutation is also a possible cause of AF genesis. Loss of function of *KCNJ5* may result in long QT syndrome and AF [35]. A previous study revealed that germline *KCNJ5* mutations are also associated with early-onset lone AF in Caucasians [36], while novel molecules targeting mutant *KCNJ5* potassium channels are under development to treat bradyarrhythmia and AF [37].

### Arterial hypertension and ventricular remodeling

Chronic hypertension results in left ventricular hypertrophy [38] and diastolic dysfunction and consequently elevation of left ventricular end diastolic pressure [39], and it is a major risk factor for AF [40]. Left ventricular diastolic dysfunction and elevated left ventricular end diastolic pressure result in elevated left atrial pressure, structural changes, and subsequently an increased occurrence of AF [41]. In animal models, hypertension has been shown to cause left atrial remodeling, including atrial dilatation, hypertrophy, inflammatory infiltrates, interstitial fibrosis, conduction slowing and heterogeneity [42]. In clinical studies, the Framingham Heart Study revealed that levels of systolic and pulse pressures were significantly associated with increased left atrial size [43], and an increased left atrial size has been shown to contribute to the development of AF [44]. Furthermore, even after adjusting for age and sex, hypertension has been reported to remain a significant predictor of AF [45].

### Hypokalemia

Hypokalemia is defined as a low serum potassium level, and it has been reported in cases and series of AF in patients with PA [46, 47]. An epidemiological study reported that a low serum level of potassium was associated with a higher risk of AF among the general population [48] or patients after cardiac surgery [49]. The electrophysiological effects of hypokalemia include resting membrane hyperpolarization,  $\text{Na}^{+}$ - $\text{K}^{+}$  ATPase inhibition, and suppression of  $\text{K}^{+}$  channel conductance, resulting in action potential duration prolongation, reduced repolarization reserve, early afterdepolarization, delayed afterdepolarization, and automaticity [50], which may all contribute to the genesis of AF. Clinically, previous study from the German Conn's Registry reported that atrial arrhythmia was found more common in those with the hypokalemic variant (12.3%) than in those with normokalemic PA (7.8%), although the difference was not statistically significant [5].

## PA and AF: Clinical studies and implications

### Epidemiology

#### Incidence of AF in PA

In 2005, Milliez et al. reported a 12.1-fold elevated risk and a prevalence of 7.3% of AF among 124 PA patients compared to 465 EH controls with a prevalence of 0.6% [2]. Their study followed the patients for 3 years, after which the PA patients also held a 4.2-fold higher risk of stroke than the EH controls. Although the sample size

was relatively small, the study provided initial and early evidence of the additional cardiovascular risk of PA over EH after blood pressure had been matched between the two groups. In 2008, Catena et al. reported an elevated odds ratio of 4.93 for sustained arrhythmia among 54 PA patients compared with EH controls, although the definition of sustained arrhythmia included arrhythmia other than AF [51]. In 2009, the German Conn's Registry reported a prevalence rate of AF of 7.1 % among 553 of 640 PA patients, and atrial arrhythmia was more common in those with the hypokalemic variant (12.3 %) than in those with normokalemic PA (7.8 %) without statistical significance [5]. In addition, Savard et al. reported a significantly higher prevalence of AF of 3.9 % with an adjusted odds ratio of 5.0 among 459 PA patients compared to 1290 EH controls in whom the prevalence was 1.1 % [52]. Moreover, Mulatero et al. reported that sustained arrhythmias (AF, atrial flutter, sustained ventricular tachycardia, and ventricular fibrillation) were significantly more common among 270 PA patients after 12 years of follow-up with an odds ratio of 2.2 compared to EH patients [53]. In 2018, the JPAS Study Group further reported a prevalence of AF of 2.8 % in a multi-center, nationwide, and large cohort of 2582 PA patients over a 10-year period [54]. Furthermore, Monticone et al. reported a 3.52-fold higher risk of AF in 3838 PA patients compared to 9284 EH controls in a meta-analysis of 31 studies over a median period of 8.8 years [3]. These data provide evidence of the strong association between aldosterone and AF in addition to the results reported in the aforementioned basic studies.

### Incidence of PA in AF

An elevated risk of AF in patients with PA has been reported in numerous clinical studies as discussed above, however, the risk and prevalence of PA among patients with AF has been less studied. Mourtzinis et al. reported that screening for PA using the aldosterone to renin ratio resulted in the diagnosis of four cases of PA in 149 AF patients (2.6 %) in 2017 [55]. In 2018, the same group reported a prevalence of PA of 0.056 % among 713 569 AF patients, compared with 0.024 % in AF-naive controls using a Swedish national registry [56]. A multicenter prospective study (PAPPHY) further reported increased prevalence of PA among hypertensive patients with unexplained AF [57].

### Clinical evidence associated with the occurrence of AF in PA

#### Left atrium structure and function

Since electrical abnormalities often originate from the left atrium, AF is associated with left atrial function [7, 58]. Left atrium function is evaluated using echocardiographic studies, from left atrium diameter, left atrial volume index (LAVI), or left atrial strain analysis [59]. Dilatation of the left atrium and an increase in volume has been positively correlated with the pathogenesis of AF [58]. In 2017, Yang et al. reported a higher LAVI among 100 PA patients compared to 100 EH controls [60]. Our previous investigation of left ventricular subclinical systolic dysfunction using strain analysis also showed a higher left atrial diameter and LAVI among PA patients compared to those among matched EH controls, although the difference did not reach statistical significance [61]. Wang et al. recently reported increased left atrial stiffness in 107 PA patients with lower left

atrial velocity, strain, and strain rate, and higher left atrial stiffness index compared to 50 EH controls [62].

#### Left ventricular structure and function

Left ventricular hypertrophy (LVH) with increased left ventricular mass is a key indicator of diastolic dysfunction [38], and diastolic dysfunction is currently considered to be a potential risk factor for the pathogenesis of AF [41]. Numerous previous clinical studies have reported more LVH and increased left ventricular mass index (LVMI) among PA patients compared to EH controls.

In 1996, Rossi et al. reported significantly increased left ventricular wall thickness and LVMI among 34 patients with PA matched to 34 EH controls with a higher percentage of LVH and concentric remodeling [12]. In 2005, Stowasser et al. reported increased left ventricular wall thicknesses and reduced diastolic function using Doppler studies among patients with familial hyperaldosteronism type I [63]. In 2007, Catena et al. reported greater left ventricular mass and more LVH among 54 PA patients compared with 274 EH controls [64]. In 2008, Muiessan et al. investigated left ventricular geometry with more inappropriate left ventricular mass derived from the difference between measured LVMI and predicted LVMI in 125 PA patients compared to 125 EH patients [65]. In 2016, Cesari et al. reported increased left ventricular enlargement and high prevalence of LVH and diastolic dysfunction using Doppler and tissue Doppler studies among 262 PA patients [66]. In our previous study of 30 adrenal adenoma patients, we found a significantly decreased LVMI in patients with LVH after adrenalectomy [67]. We also reported the significant positive predictive ability of 24-hour urinary aldosterone to LVMI and inappropriate LVMI among PA patients, as well as tissue-Doppler studies measuring diastolic dysfunction [68, 69].

#### Autonomic dysfunction

Autonomic dysfunction has been reported in PA patients with reversible sympathetic overactivity before and after adrenalectomy [70]. Heart rate variability (HRV) has been shown to be a valid tool to evaluate autonomic nerve system [71], and to be a potential predictor of AF in middle-aged individuals [72]. Left atrium dilatation has been correlated with decreased HRV [73]. A recent study further reported an association between decreased HRV and a higher incidence of AF in a large cohort with long-term follow-up, as a presentation of cardiac autonomic dysfunction [74]. In 1995, Veglio et al. reported impaired heart rate and blood pressure variability when responding to tilt in 17 PA patients compared to 11 EH controls [75]. We previously reported comparable conventional HRV parameters but decreased heart rhythm complexity among 20 PA patients compared to 25 EH controls, and partial reversal of heart rhythm complexity impairment after adrenalectomy in PA patients [76]. Impairment of HRV or heart rhythm complexity may contribute AF genesis. However, the relations between HRV and AF in PA patients are still unclear and need further studies.

### Treatment of PA and the effect on AF

#### Correction of hypertension and hypokalemia and targeted treatment for excessive aldosterone

Treatment with antihypertensive agents for elevated blood pressure and potassium supplements has been shown to reduce the

risk of AF in several hypertension trials [77]. PA has been shown to be associated with a much higher cardiovascular risk than age-, sex-, and BP-matched EH patients in a clinical study and meta-analysis [2, 3], and other clinical studies have shown that targeted treatment is beneficial for hypertensive patients [51, 78, 79].

The targeted treatment for PA recommended in current guidelines is unilateral laparoscopic adrenalectomy for patients with documented unilateral PA to cure hyperaldosteronism and hypokalemia and cure or substantially reduce elevated blood pressure. For those with bilateral PA and unilateral PA not receiving surgery, medical treatment with an MRA is suggested to lower both blood pressure and the deleterious effects of aldosterone hypersecretion [1].

### Surgical adrenalectomy

With regards to the occurrence of AF in PA, the results of the PAPY study, a large prospective registry of 107 PA patient and 894 EH patients with a median 11.8 years of follow-up reported in 2018 by Rossi et al., demonstrated a trend of a higher risk of NOAF among the PA patients receiving treatment than the EH patients. In addition, the surgically treated PA patients had a similar AF-free survival rate compared to the optimally treated EH patients, while the medically treated PA patients still had a higher risk of AF [80]. Hundemer et al. performed a retrospective chart review study of 396 PA patients, of whom 201 received adrenalectomy, and 40092 EH patients, and found no significant difference in the risk of NOAF between the PA patients treated with surgical adrenalectomy and the patients with EH [81]. In our recent publication using the large nationwide National Health Insurance Research Database (NHIRD) of Taiwan, we found a lower risk of NOAF in 534 PA patients receiving surgical adrenalectomy compared to matched EH patients [82].

### Mineralocorticoid receptor antagonists

PA patients receiving MRA treatment in the PAPY study had a higher risk of AF and decreased AF-free survival [80]. In the retrospective study of Hundemer et al. consisting of 396 PA and 40092 EH patients, 195 of the PA patients received MRAs and had different outcomes with regards to NOAF according to post-treatment plasma renin activity level, with a cut-off point of 1 ng/ml/h as a proxy for insufficient or sufficient MR blockade. In addition, the PA patients treated with MRAs with suppressed renin activity and insufficient MR blockade had a higher risk of NOAF than the EH patients, with an adjusted hazard ratio of 2.55. In comparison, the PA patients treated with MRAs with increased renin activity and sufficient MR blockade did not have a statistically significant difference in the risk of NOAF compared to the EH patients [81]. Another larger retrospective study reported by Hundemer et al. with 602 MRA-treated PA patients and 41 853 age-matched EH patients showed a hazard ratio of AF of 1.93 compared with the EH patients, and the PA patients with insufficient MR blockade had a higher risk of cardiovascular events and mortality compared to the PA patients with sufficient blockade [83]. Post-treatment renin activity may reflect the adequacy of MR blockade and further guide the dosage of MRAs to improve cardiovascular outcomes and the risk of NOAF.

These three studies demonstrated a higher risk of NOAF among PA patients receiving MRAs. In our recent publication using the NHIRD, we also found increased risks of NOAF and major adverse

cardiovascular and cerebro-cardiovascular events in 1668 PA patients receiving MRAs compared with matched EH patients [82].

### Reversal of left ventricular mass/echocardiographic parameters

Rossi et al. found that patients with hyperaldosteronism had increased left ventricular wall thickness and mass and impaired early diastolic left ventricular filling indexes compared with EH patients, and that these effects could be reversed 1 year after adrenalectomy with maintenance therapy after 5 or 10 years of follow-up [84, 85]. In addition, Cetena et al. found that both adrenalectomy and spironolactone in PA patients had a comparable effect on reducing left ventricular mass after a mean follow-up period of 6.4 years [64]. Indra et al. showed that adrenalectomy was more effective in reducing left ventricular mass reduction and left ventricular wall thickening and reversing left ventricular cavity enlargement, while spironolactone only reduced left ventricular cavity size [86]. Our group also previously demonstrated the regression of left ventricular mass in patients receiving adrenalectomy [87]. In addition, the improvement after adrenalectomy was seen in both reversal of left ventricular geometry and also alterations in myocardial texture, as shown by increased cyclic variation of integrated backscatter (CVIBS) and decreased plasma carboxy-terminal propeptide of procollagen type I (PICP) level [88]. We also previously reported that aldosterone-induced left ventricular diastolic dysfunction could be reversed after adrenalectomy [89]. Because of the close relation between left ventricular structure/function and AF genesis, improvement of left ventricular structure/function after PA target treatment may further decrease AF burden.

### Future perspectives and other hot topics associated with AF in PA

#### KCNJ5 somatic mutations, primary aldosteronism, and atrial fibrillation

Several somatic mutations have been found to be highly correlated or causative for PA [34]. Of notice, *KCNJ5* gene mutations, largely seen in aldosterone-producing adrenal adenomas [90, 91], are considered to be the most common somatic mutations in PA [34, 92]. *KCNJ5* mutations have been reported to result in the loss of ion selectivity to cause cell membrane depolarization and increased  $\text{Ca}^{2+}$  entry in adrenal glomerulosa cells and to increase aldosterone synthesis, and *KCNJ5* mutation-related potassium channelopathy is considered to be an important contributor to the pathogenesis of PA [91]. Among PA patients with somatic *KCNJ5* mutations, higher plasma aldosterone level and LVMI [93], younger age, and more female gender were reported over PA patients without somatic *KCNJ5* mutations [94], with higher rate of cure of hypertension after adrenalectomy [95]. However, the relations between somatic *KCNJ5* mutation and AF are not clear and further studies are warranted.

#### Subclinical Cushing syndrome, primary aldosteronism, and atrial fibrillation

Subclinical Cushing syndrome has been found to co-exist with certain types of PA [96], and adrenal-cortical tumors have been shown to have great heterogeneity and complexity in clinical, morphological, and molecular presentation [97]. Tang et al. reported 22



patients with aldosterone- and cortisol-coproducing adrenal adenomas among 555 PA patients, and found a higher risk of heart disease including AF compared with 392 adrenal adenoma patients [98]. It is not currently known whether Cushing syndrome is correlated with AF. A previous echocardiographic study showed that patients with Cushing syndrome had a greater reduction in left atrial ejection fraction and increased left ventricular mass and wall thickness compared with EH controls, which were corrected after treatment [99]. In addition, iatrogenic Cushing syndrome with exogenous steroid use has been positively associated with the incidence of AF [100]. Further studies are warranted to investigate the relationships among subclinical Cushing syndrome, PA, and AF.

### New treatment targeting aldosterone excess

Newer potential alternatives for surgical adrenalectomy with CT-guided radiofrequency ablation have shown promising results [101], however further long-term outcomes and effects on AF need to be confirmed. The investigational new drug LCI699 has been shown to inhibit aldosterone synthase and to provide a fair short-term effect, however long-term data are lacking [102]. Newer generations of novel non-steroidal MRAs including finerenone (BAY 94–8862) and esaxerenone (CS-3150) have been evaluated in pre-clinical and clinical trials and have shown the potential to treat PA, however their effects on AF and long-term mortality have not been well studied [103]. In addition, for concurrent MRA treatment with spironolactone and eplerenone, the optimal dosage has not definitively been established. The current guidelines for spironolactone recommend from 12.5 mg per day with slow titration to a maximum dose of daily 100 mg, and for eplerenone 25 mg twice daily with the goals of normalizing serum potassium, reduce blood pressure, and eliminating the vascular, cardiac, and renal effects of aldosterone with a minimum number of drugs and side effects [1]. Further studies to investigate the optimal dosage of MRAs to prevent AF are also needed. Further studies are also needed to elucidate whether surgical adrenalectomy can convert pre-existing AF among PA patients. For PA patients with sinus rhythm, the risk factors for developing AF also need to be identified.

## Conclusion

PA with excessive aldosterone poses an additional risk of AF as evidenced in clinical trials and basic studies. Further studies are still needed to elucidate the relationship between PA and AF. In-depth investigations are also needed to study the unique pathogenesis of AF in PA patients with a genetic preference or late disease progression and related complications. Further clinical trials are required to evaluate the risk of NOAF with different PA treatments and the long-term outcomes in patients with different subtypes of PA. With a higher level of suspicion and prompt surveys for PA in specific clinical scenarios, more precise therapeutic strategies to improve the management and outcomes of patients with PA can be anticipated.

### Appendix [the TAIPI Study Group]

Membership of the Taiwan Primary Aldosteronism Investigation (TAIPI) Study Group: Che-Hsiung Wu, MD (Chi-Taz hospital, PI of Committee); Vin-Cent Wu, MD, PhD (NTUH, PI of Committee); Yen-

Hung Lin, MD, PhD (NTUH, PI of Committee); Yi-Luwn Ho, MD, PhD (NTUH, PI of Committee); Hung-Wei Chang, MD, PhD (Far Eastern Hospital, PI of Committee); Lian-Yu Lin MD, PhD (NTUH, PI of Committee); Fu-Chang Hu, MS, ScD, (Harvard Statistics, Site Investigator); Kao-Lang Liu, MD (NTUH, PI of Committee); Shuo-Meng Wang, MD (NTUH, PI of Committee); Kuo-How Huang, MD, PhD (NTUH, PI of Committee); Yung-Ming Chen, MD (NTUH, PI of Committee); Chin-Chi Kuo; MD (Yun-Lin, PI of Committee), Chin-Chen Chang, MD (NTUH, PI of Committee); Shih-Cheng Liao, MD, PhD (NTUH, PI of Committee); Ruoh-Fang Yen, MD, PhD (NTUH, PI of Committee); and Kwan-Dun Wu, MD, PhD (NTUH, Director of Coordinating Center).

## Funding

This research was supported by grants from the Ministry of Science and Technology (MOST 106–2314-B-002–048 –MY3 and MOST 106–2314-B-002–169-MY3) and National Taiwan University Hospital (NTUH 107-A141).

## Conflict of Interest

The authors declare that they have no conflict of interest.

## References

- [1] Funder JW, Carey RM, Mantero F et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2016; 101: 1889–1916
- [2] Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol* 2005; 45: 1243–1248
- [3] Monticone S, D'Ascenzo F, Moretti C et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 2018; 6: 41–50
- [4] Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur J Cardiothorac Surg* 2016; 50: e1–e88
- [5] Born-Frontsberg E, Reincke M, Rump LC et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. *J Clin Endocrinol Metab* 2009; 94: 1125–1130
- [6] Staerk L, Sherer JA, Ko D et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. *Circ Res* 2017; 120: 1501–1517
- [7] Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. *J Am Coll Cardiol* 2015; 65: 2239–2251
- [8] Gravez B, Tarjus A, Jaisser F. Mineralocorticoid receptor and cardiac arrhythmia. *Clin Exp Pharmacol Physiol* 2013; 40: 910–915
- [9] Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Eng J Med* 1998; 339: 659–666
- [10] Hove-Madsen L, Llach A, Bayes-Genis A et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. *Circulation* 2004; 110: 1358–1363

- [11] Burstein B, Libby E, Calderone A et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. *Circulation* 2008; 117: 1630–1641
- [12] Rossi GP, Sacchetto A, Visentin P et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. *Hypertension* 1996; 27: 1039–1045
- [13] Kozakova M, Buralli S, Palombo C et al. Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. *Hypertension* 2003; 41: 230–236
- [14] Fiebeler A, Schmidt F, Muller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappaB activation in angiotensin II-induced cardiac injury. *Hypertension* 2001; 37: (2 Pt 2) 787–793
- [15] Keidar S, Kaplan M, Pavlotzky E et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. *Circulation* 2004; 109: 2213–2220
- [16] Sun Y, Zhang J, Lu L et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. *Am J Pathol* 2002; 161: 1773–1781
- [17] Yoshida K, Kim-Mitsuyama S, Wake R et al. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. *Hypertens Res* 2005; 28: 447–455
- [18] Shen JZ, Morgan J, Tesch GH et al. Cardiac tissue injury and remodeling is dependent upon mr regulation of activation pathways in cardiac tissue macrophages. *Endocrinology* 2016; 157: 3213–3223
- [19] Usher MG, Duan SZ, Ivaschenko CY et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. *J Clin Invest* 2010; 120: 3350–3364
- [20] Oestreicher EM, Martinez-Vasquez D, Stone JR et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. *Circulation* 2003; 108: 2517–2523
- [21] Desmouliere A, Geinoz A, Gabbiani F et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. *J Cell Biol* 1993; 122: 103–111
- [22] Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? *J Cardiovasc Pharmacol* 2011; 57: 376–379
- [23] Yang Y, Chen S, Tao L et al. Inhibitory effects of oxymatrine on transdifferentiation of neonatal rat cardiac fibroblasts to myofibroblasts induced by aldosterone via Keap1/Nrf2 signaling pathways in vitro. *Med Sci Monit* 2019; 25: 5375–5388
- [24] Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. *Cardiovasc Res* 1997; 35: 138–147
- [25] Reil JC, Hohl M, Selejan S et al. Aldosterone promotes atrial fibrillation. *Eur Heart J* 2012; 33: 2098–2108
- [26] Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circ Arrhythm Electrophysiol* 2008; 1: 62–73
- [27] Heijman J, Voigt N, Nattel S et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. *Circ Res* 2014; 114: 1483–1499
- [28] Lammers C, Dartsch T, Brandt MC et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. *Cell Physiol Biochem* 2012; 29: 833–840
- [29] Agarwal YK, Aronow WS, Levy JA et al. Association of interatrial block with development of atrial fibrillation. *Am J Cardiol* 2003; 91: 882
- [30] Magnani JW, Johnson VM, Sullivan LM et al. P wave duration and risk of longitudinal atrial fibrillation in persons  $\geq$  60 years old (from the Framingham Heart Study). *Am J Cardiol* 2011; 107: 917–921 e911
- [31] Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. *Circulation* 2005; 111: 3025–3033
- [32] Gomez AM, Rueda A, Sainte-Marie Y et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. *Circulation* 2009; 119: 2179–2187
- [33] Tsai CT, Chiang FT, Tseng CD et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. *J Am Coll Cardiol* 2010; 55: 758–770
- [34] Seidel E, Schewe J, Scholl UI. Genetic causes of primary aldosteronism. *Exp Mol Med* 2019; 51: 131
- [35] Amin AS, Wilde AAM. Inheritable potassium channel diseases. In *cardiac electrophysiology: from cell to bedside*. Seventh edn Amsterdam: Elsevier, Inc; 2018: 494–503
- [36] Jabbari J, Olesen MS, Holst AG et al. Common polymorphisms in KCNJ5 [corrected] are associated with early-onset lone atrial fibrillation in Caucasians. *Cardiology* 2011; 118: 116–120
- [37] Yamada N, Asano Y, Fujita M et al. Mutant KCNJ3 and KCNJ5 potassium channels as novel molecular targets in bradyarrhythmias and atrial fibrillation. *Circulation* 2019; 139: 2157–2169
- [38] Cramariuc D, Gerds E. Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic. *Expert Rev Cardiovasc Ther* 2016; 14: 915–926
- [39] Nadruz W, Shah AM, Solomon SD. Diastolic dysfunction and hypertension. *Med Clin North Am* 2017; 101: 7–17
- [40] Lau DH, Nattel S, Kalman JM et al. Modifiable risk factors and atrial fibrillation. *Circulation* 2017; 136: 583–596
- [41] Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. *Circulation* 2012; 126: 2353–2362
- [42] Kistler PM, Sanders P, Dodic M et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. *Eur Heart J* 2006; 27: 3045–3056
- [43] Vaziri SM, Larson MG, Lauer MS et al. Influence of blood pressure on left atrial size. The framingham heart study. *Hypertension* 1995; 25: 1155–1160
- [44] Henry WL, Morganroth J, Pearlman AS et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. *Circulation* 1976; 53: 273–279
- [45] Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. *Am J Cardiol* 1998; 82: (8a) 2n–9n
- [46] Al-Aloul B, Li JM, Benditt D et al. Atrial fibrillation associated with hypokalemia due to primary hyperaldosteronism (Conn's syndrome). *Pacing Clin Electrophysiol* 2006; 29: 1303–1305
- [47] Watson T, Karthikeyan VJ, Lip GY et al. Atrial fibrillation in primary aldosteronism. *J Renin Angiotensin Aldosterone Syst* 2009; 10: 190–194
- [48] Krijthe BP, Heeringa J, Kors JA et al Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. *Int J Cardiol* 2013; 168: 5411–5415
- [49] Auer J, Weber T, Berent R et al. Serum potassium level and risk of postoperative atrial fibrillation in patients undergoing cardiac surgery. *J Am Coll Cardiol* 2004; 44: 938–939 author reply 939
- [50] Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. *Circ Arrhythm Electrophysiol* 2017; 10: pii e004667 . doi: 10.1161/CIRCEP.116.004667
- [51] Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. *Arch Intern Med* 2008; 168: 80–85

- [52] Savard S, Amar L, Plouin PF et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. *Hypertension* 2013; 62: 331–336
- [53] Mulatero P, Monticone S, Bertello C et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. *J Clin Endocrinol Metab* 2013; 98: 4826–4833
- [54] Ohno Y, Sone M, Inagaki N et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. *Hypertension* 2018; 71: 530–537
- [55] Mourtzinis G, Ebrahimi A, Gustafsson H et al. Aldosterone to renin ratio as a screening instrument for primary aldosteronism in a middle-aged population with atrial fibrillation. *Horm Metab Res* 2017; 49: 831–837
- [56] Mourtzinis G, Adamsson Eryd S, Rosengren A et al. Primary aldosteronism and thyroid disorders in atrial fibrillation: a Swedish nationwide case-control study. *Eur J Prev Cardiol* 2018; 25: 694–701
- [57] Seccia TM, Letizia C, Muiesan ML et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. *J Hypertens* 2020; 38: 332–339
- [58] Hoit BD. Left atrial size and function: role in prognosis. *J Am Coll Cardiol* 2014; 63: 493–505
- [59] Nagueh SF, Smiseth OA, Appleton CP et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. *J Am Soc Echocardiogr* 2016; 29: 277–314
- [60] Yang Y, Zhu LM, Xu JZ et al. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. *Hypertens Res* 2017; 40: 243–250
- [61] Chen ZW, Huang KC, Lee JK et al. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. *J Hypertens* 2018; 36: 353–360
- [62] Wang D, Xu JZ, Chen X et al. Left atrial myocardial dysfunction in patients with primary aldosteronism as assessed by speckle-tracking echocardiography. *J Hypertens* 2019; 37: 2032–2040
- [63] Stowasser M, Sharman J, Leano R et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. *J Clin Endocrinol Metab* 2005; 90: 5070–5076
- [64] Catena C, Colussi G, Lapenna R et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. *Hypertension* 2007; 50: 911–918
- [65] Muiesan ML, Salvetti M, Paini A et al. Inappropriate left ventricular mass in patients with primary aldosteronism. *Hypertension* 2008; 52: 529–534
- [66] Cesari M, Letizia C, Angeli P et al. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue doppler study. *Circ Cardiovasc Imaging* 2016; 9: pii e004815. doi: 10.1161/CIRCIMAGING.116.004815
- [67] Lin YH, Huang KH, Lee JK et al. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. *J Renin Angiotensin Aldosterone Syst* 2011; 12: 48–53
- [68] Hung CS, Ho YL, Chang YY et al. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. *Sci World J.* 2013; 294594
- [69] Chang YY, Lee HH, Hung CS et al. Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. *Clin Biochem* 2014; 47: 1329–1332
- [70] Kontak AC, Wang Z, Arbique D et al. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. *J Clin Endocrinol Metab* 2010; 95: 4756–4761
- [71] Khan AA, Lip GYH, Shantsila A. Heart rate variability in atrial fibrillation: the balance between sympathetic and parasympathetic nervous system. *Eur J Clin Invest* 2019; 49: e13174
- [72] Perkiomaki J, Ukkola O, Kiviniemi A et al. Heart rate variability findings as a predictor of atrial fibrillation in middle-aged population. *J Cardiovasc Electrophysiol* 2014; 25: 719–724
- [73] Friedman HS. Heart rate variability in atrial fibrillation related to left atrial size. *Am J Cardiol* 2004; 93: 705–709
- [74] Agarwal SK, Norby FL, Whitsel EA et al. Cardiac autonomic dysfunction and incidence of atrial fibrillation: results from 20 years follow-up. *J Am Coll Cardiol* 2017; 69: 291–299
- [75] Veglio F, Melchio R, Rabbia F et al. Spectral characteristics of heart rate and blood pressure variability in primary aldosteronism. *Am J Hypertens* 1995; 8: (5 Pt 1) 479–486
- [76] Lin YH, Wu VC, Lo MT et al. Reversible heart rhythm complexity impairment in patients with primary aldosteronism. *Sci Rep* 2015; 5: 11249
- [77] Dzeshka MS, Shantsila A, Shantsila E et al. Atrial fibrillation and hypertension. *Hypertension* 2017; 70: 854–861
- [78] Reincke M, Fischer E, Gerum S et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. *Hypertension* 2012; 60: 618–624
- [79] Liao CW, Lin LY, Hung CS et al. Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients. *Sci Rep* 2016; 6: 20862
- [80] Rossi GP, Maiolino G, Flego A et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. *Hypertension* 2018; 71: 585–591
- [81] Hundemer GL, Curhan GC, Yozamp N et al. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. *JAMA Cardiol* 2018; 3: 768–774
- [82] Pan CT, Liao CW, Tsai CH et al. Influence of different treatment strategies on new-onset atrial fibrillation among patients with primary aldosteronism: a nationwide longitudinal cohort-based study. *J Am Heart Assoc* 2020; 9: e013699
- [83] Hundemer GL, Curhan GC, Yozamp N et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. *Lancet Diabetes Endocrinol* 2018; 6: 51–59
- [84] Rossi GP, Cesari M, Cuspidi C et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. *Hypertension* 2013; 62: 62–69
- [85] Rossi GP, Sacchetto A, Pavan E et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. *Circulation* 1997; 95: 1471–1478
- [86] Indra T, Holaj R, Štrauch B et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. *J Renin Angiotensin Aldosterone Syst* 2015; 16: 1109–1117
- [87] Lin YH, Huang KH, Lee JK et al. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. *J Renin Angiotensin Aldosterone Syst* 2011; 12: 48–53
- [88] Lin YH, Lee HH, Liu KL et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. *Surgery* 2011; 150: 526–533
- [89] Chang YY, Liao CW, Tsai CH et al. Left ventricular dysfunction in patients with primary aldosteronism: a propensity score-matching follow-up study with tissue doppler imaging. *J Am Heart Assoc* 2019; 8: e013263



- [90] Choi M, Scholl UI, Yue P et al. K<sup>+</sup> channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science* 2011; 331: 768–772
- [91] Gomez-Sanchez CE, Oki K. Minireview: potassium channels and aldosterone dysregulation: is primary aldosteronism a potassium channelopathy? *Endocrinology* 2014; 155: 47–55
- [92] Williams TA, Monticone S, Mulatero P. KCNJ5 mutations are the most frequent genetic alteration in primary aldosteronism. *Hypertension* 2015; 65: 507–509
- [93] Rossi GP, Cesari M, Letizia C et al. KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. *J Hypertens* 2014; 32: 1514–1521 discussion 1522
- [94] Lenzini L, Rossitto G, Maiolino G et al. A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. *J Clin Endocrinol Metab* 2015; 100: E1089–E1095
- [95] Wu VC, Huang KH, Peng KY et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. *Sci Rep* 2015; 5: 11396
- [96] Fujimoto K, Honjo S, Tatsuoka H et al. Primary aldosteronism associated with subclinical Cushing syndrome. *J Endocrinol Invest* 2013; 36: 564–567
- [97] Spath M, Korovkin S, Antke C et al. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. *Eur J Endocrinol* 2011; 164: 447–455
- [98] Tang L, Li X, Wang B et al. Clinical characteristics of aldosterone- and cortisol-coproducing adrenal adenoma in primary aldosteronism. *Int J Endocrinol*. 2018; 4920841:
- [99] Kamenicky P, Redheuil A, Roux C et al. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. *J Clin Endocrinol Metab* 2014; 99: E2144–E2153
- [100] van der Hooft CS, Heeringa J, Brusselle GG et al. Corticosteroids and the risk of atrial fibrillation. *Arch Intern Med* 2006; 166: 1016–1020
- [101] Liu SY, Chu CC, Tsui TK et al. Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation-long-term results and recurrence rate. *Radiology* 2016; 281: 625–634
- [102] Amar L, Azizi M, Menard J et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. *Hypertension* 2010; 56: 831–838
- [103] Morimoto R, Omata K, Ito S et al. Progress in the management of primary aldosteronism. *Am J Hypertens* 2018; 31: 522–531